Sep 26, 2026
Akebia Therapeutics, Inc. $AKBA Position Reduced by State Street Corp
State Street Corp significantly reduced its stake in Akebia Therapeutics (NASDAQ:AKBA) by 53.6% in the second quarter, selling over 6.2 million shares. Despite this, other institutional investors have either increased or initiated positions in the biopharmaceutical company. Akebia Therapeutics reported better-than-expected Q2 earnings and revenue, with its lead product Vafseo approved for anemia associated with chronic kidney disease in dialysis patients.
Company relevance
100.00%
Company sentiment
Neutral
Overall sentiment
Neutral
Sep 14, 2026
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases
Akebia Therapeutics has dosed the first patient in its Phase 2 basket trial for ebribafusp, an investigational treatment for rare complement-mediated kidney diseases like IgA nephropathy, lupus nephritis, and C3 glomerulopathy. Ebribafusp is designed to specifically inhibit complement activation in kidney tissues without affecting the systemic complement system, aiming to offer a long-term treatment option with reduced infection risk. Initial data from the open-label trial, which will enroll up to 30 patients, is anticipated in 2027.
Company relevance
100.00%
Company sentiment
Bullish
Overall sentiment
Bullish